{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:47:18Z","timestamp":1760014038336},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["141170\/2011-5"],"award-info":[{"award-number":["141170\/2011-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejps.2017.05.033","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T02:00:55Z","timestamp":1494900055000},"page":"S108-S115","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S","title":["Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients"],"prefix":"10.1016","volume":"109","author":[{"given":"Glauco H.B.","family":"Nardotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera L.","family":"Lanchote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo B.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.05.033_bb0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cpt.143","article-title":"Cardiovascular risk in diabetes mellitus: complication of the disease or of antihyperglycemic medications","volume":"98","author":"Alvarez","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.05.033_bb0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/HYPERTENSIONAHA.111.189589","article-title":"Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome","volume":"59","author":"Ayers","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejps.2017.05.033_bb0015","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejps.2017.05.033_bb0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/sj.bjp.0706283","article-title":"New positron emission tomography tracer [11C] carvedilol reveals P-glycoprotein modulation kinetics","volume":"145","author":"Bart","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0025","article-title":"NONMEM users guide: introduction to NONMEM 7.2.0","author":"Bauer","year":"2011","journal-title":"ICON Dev. Solut."},{"key":"10.1016\/j.ejps.2017.05.033_bb0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1463-1326.2008.00927.x","article-title":"Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients","volume":"11","author":"Bell","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejps.2017.05.033_bb0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/bcp.12473","article-title":"Population pharmacokinetics of deferiprone in healthy subjects","volume":"78","author":"Bellanti","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0040","article-title":"Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6years","volume":"1\u201310","author":"Bellanti","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0045","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1074\/jbc.M110.155200","article-title":"Recognition of sulfonylurea receptor (ABCC8\/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1). Functional similarities based on common structural features between two multispecific abc proteins","volume":"286","author":"Bessadok","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2017.05.033_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.ejps.2017.05.033_bb0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2017.05.033_bb0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CP202158","article-title":"Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.05.033_bb9820","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(85)91900-2","article-title":"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion","volume":"325","author":"Dornhorst","year":"1985","journal-title":"The Lancet"},{"key":"10.1016\/j.ejps.2017.05.033_bb0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03261926","article-title":"Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs","volume":"51","author":"Dostalek","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.05.033_bb0070","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/02664763.2014.999650","article-title":"The total bootstrap median: a robust and efficient estimator of location and scale for small samples","volume":"42","author":"Dowd","year":"2015","journal-title":"J. Appl. Stat."},{"key":"10.1016\/j.ejps.2017.05.033_bb0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1081\/BIP-200040824","article-title":"Analysis of population pharmacokinetic data using nonmem and winbugs","volume":"15","author":"Duffull","year":"2004","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.ejps.2017.05.033_bb0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0378-4347(00)82713-9","article-title":"High-performance liquid chromatographic method for the simultaneous determination of the enantiomers of carvedilol and its O-desmethyl metabolite in human plasma after chiral derivatization","volume":"493","author":"Eisenberg","year":"1989","journal-title":"J. Chromatogr. B. Biomed. Sci. App."},{"key":"10.1016\/j.ejps.2017.05.033_bb0095","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-011-1554-7","article-title":"Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer","volume":"68","author":"Fernandes","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0100","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1464-5491.2007.02151.x","article-title":"Differential effect of \u03b2-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI","volume":"24","author":"Fonseca","year":"2007","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejps.2017.05.033_bb0105","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpba.2012.05.026","article-title":"A validated enantioselective LC\u2013MS\/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4\u2032-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study","volume":"70","author":"Furlong","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2017.05.033_bb0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clpt.2003.10.004","article-title":"CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects","volume":"75","author":"Giessmann","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.05.033_bb0115","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-126-12-199706150-00004","article-title":"Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial","volume":"126","author":"Giugliano","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejps.2017.05.033_bb0120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s004240050829","article-title":"P-glycoprotein inhibition by glibenclamide and related compounds","volume":"437","author":"Golstein","year":"1999","journal-title":"Pfl\u00fcg. Arch."},{"key":"10.1016\/j.ejps.2017.05.033_bb0125","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.05.033_bb0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000340020","article-title":"Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes","volume":"90","author":"Hanioka","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejps.2017.05.033_bb9815","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0895-7061(03)00062-1","article-title":"Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control","volume":"16","author":"Holzgreve","year":"2003","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejps.2017.05.033_bb0135","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1517\/17425255.2012.722619","article-title":"CYP2C metabolism of oral antidiabetic drugs \u2014 impact on pharmacokinetics, drug interactions and pharmacogenetic aspects","volume":"8","author":"Holstein","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0140","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.05.033_bb0145","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1248\/bpb.31.1297","article-title":"Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes","volume":"31","author":"Ishida","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2017.05.033_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jchromb.2005.05.011","article-title":"A highly sensitive LC\u2013MS\u2013MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism","volume":"822","author":"Jabor","year":"2005","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejps.2017.05.033_bb0155","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00004872-199604000-00012","article-title":"Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study","volume":"14","author":"Jacob","year":"1996","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejps.2017.05.033_bb0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1208\/s12248-012-9320-2","article-title":"Covariate pharmacokinetic model building in oncology and its potential clinical relevance","volume":"14","author":"Joerger","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2017.05.033_bb0165","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dom.12024","article-title":"Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin","volume":"15","author":"Kasichayanula","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejps.2017.05.033_bb0170","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1124\/dmd.31.9.1090","article-title":"Inhibitory effect of glyburide on human cytochrome P450 isoforms in human liver microsomes","volume":"31","author":"Kim","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.05.033_bb0175","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","article-title":"Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (\u2212)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers","volume":"74","author":"Kirchheiner","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.05.033_bb0180","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2017.05.033_bb0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.ejps.2017.05.033_bb0190","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01061662","article-title":"A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam","volume":"19","author":"Maitre","year":"1991","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2017.05.033_bb0195","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/pgs.11.65","article-title":"Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective","volume":"12","author":"Manolopoulos","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2017.05.033_bb0200","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2337\/dc13-1276","article-title":"The pharmacogenetics of type 2 diabetes: a systematic review","volume":"37","author":"Maruthur","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejps.2017.05.033_bb0205","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF00544245","article-title":"Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker","volume":"33","author":"M\u00f6llendorff","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jchromb.2016.02.028","article-title":"Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical pharmacokinetic study","volume":"1015\u20131016","author":"Nardotto","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejps.2017.05.033_bb0215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/jcph.864","article-title":"Effects of type 2 diabetes mellitus in patients on treatment with glibenclamide and metformin on carvedilol enantiomers metabolism","volume":"57","author":"Nardotto","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03189969","article-title":"Metabolism of carvedilol in man","volume":"16","author":"Neugebauer","year":"1991","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"Suppl. 11","key":"10.1016\/j.ejps.2017.05.033_bb0225","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/00005344-198710004-00015","article-title":"Pharmacokinetics and disposition of carvedilol in humans","volume":"10","author":"Neugebauer","year":"1987","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0230","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1007\/BF01409476","article-title":"Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound","volume":"38","author":"Neugebauer","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0235","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bcp.12917","article-title":"Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers","volume":"82","author":"Neves","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.32.2.235","article-title":"Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol","volume":"32","author":"Ohno","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.05.033_bb0245","first-page":"970","article-title":"In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(\u2212)-carvedilol","volume":"25","author":"Oldham","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.05.033_bb0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s13318-014-0245-2","article-title":"The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro","volume":"41","author":"Pan","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.05.033_bb0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.ejps.2017.05.033_bb0260","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bcp.12247","article-title":"Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children: lamivudine pharmacokinetics in children","volume":"77","author":"Piana","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2017.05.033_bb0270","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejps.2017.05.033_bb0275","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00007691-199206000-00002","article-title":"Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations","volume":"14","author":"Sohn","year":"1992","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.05.033_bb0285","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-011-1013-8","article-title":"Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients","volume":"67","author":"Surendiran","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0290","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00001813-200404000-00001","article-title":"Carvedilol: a new candidate for reversal of MDR1\/P-glycoprotein-mediated multidrug resistance","volume":"15","author":"Takara","year":"2004","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ejps.2017.05.033_bb0295","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1248\/bpb.30.2146","article-title":"Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity","volume":"30","author":"Takekuma","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2017.05.033_bb0300","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/00912700022009576","article-title":"Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure","volume":"40","author":"Tenero","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0305","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2796.2010.02257.x","article-title":"Potential CYP2C9-mediated drug\u2013drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide","volume":"268","author":"Tirkkonen","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejps.2017.05.033_bb0310","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/hrt.2006.092379","article-title":"Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)","volume":"93","author":"Torp-Pedersen","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.ejps.2017.05.033_bb0315","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2337\/diab.12.5.414","article-title":"Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease","volume":"12","author":"Ueda","year":"1963","journal-title":"Diabetes"},{"key":"10.1016\/j.ejps.2017.05.033_bb0320","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","article-title":"Assessment of actual significance levels for covariate effects in NONMEM","volume":"28","author":"W\u00e4hlby","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2017.05.033_bb0325","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/ps040427","article-title":"Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis","volume":"4","author":"W\u00e4hlby","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ejps.2017.05.033_bb0330","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1210\/en.2013-2013","article-title":"Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability","volume":"155","author":"Wang","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejps.2017.05.033_bb0335","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2017.05.033_bb0340","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check","volume":"28","author":"Yano","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2017.05.033_bb0345","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/bcp.12024","article-title":"Population pharmacokinetics of abacavir in infants, toddlers and children: population pharmacokinetics of abacavir in children","volume":"75","author":"Zhao","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.033_bb0350","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0009-9236(95)90036-5","article-title":"Stereoselective disposition of carvedilol is determined by CYP2D6","volume":"57","author":"Zhou","year":"1995","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T20:54:58Z","timestamp":1535835298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717302622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":69,"alternative-id":["S0928098717302622"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.05.033","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}